What condition is Casgevy (exagamglogene autotemcel) approved to treat?
Casgevy is used to treat sickle cell disease. It is given to patients who have a specific blood-cell problem caused by sickle hemoglobin (HbS), typically including people with severe disease who are at high risk for complications.
Casgevy is also used for transfusion-dependent beta thalassemia (a different inherited blood disorder) in people who have been receiving regular blood transfusions.
How does Casgevy work in the body?
Casgevy is a gene therapy that uses a patient’s own blood-forming cells. Doctors collect stem cells, then modify them so they can produce fetal hemoglobin (HbF). Higher HbF helps reduce sickling of red blood cells in sickle cell disease and can lessen the severity of anemia in beta thalassemia.
Is Casgevy a transplant?
Casgevy is not the same as a traditional donor stem-cell transplant. It uses the patient’s own cells (an autologous approach), but the therapy still involves a process similar to transplant care: cell collection, gene modification, and then giving the modified cells back after chemotherapy conditioning.
Who is it used for in practice?
People considered for Casgevy are generally those with severe, clinically significant disease in either sickle cell disease or transfusion-dependent beta thalassemia, where standard care has not been enough. Eligibility also depends on medical factors such as overall health and ability to tolerate the conditioning chemotherapy needed before infusion.
Sources
No sources were provided in the prompt.